AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...
Myelofibrosis belongs to a group of rare diseases called myeloproliferative neoplasms, which are types of blood cancer. These neoplasms can progress to acute myeloid leukemia (AML). In ...
The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
Acute myeloid leukemia (AML) is a progressive type of cancer that affects your bone marrow and blood cells. Early detection and treatment are important to help increase the chances of survival from ...
The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...
Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...
Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper infrastructure, while treatment decisions are based on intensive vs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results